Domatinostat | 4SC-202 free base | Apoptosis Inducer | AmBeed-信号通路专用抑制剂

首页 / / / 组蛋白去乙酰化酶 / Domatinostat

Domatinostat {[allProObj[0].p_purity_real_show]}

货号：A161236 同义名： 4SC-202 free base; 4SC-202

Domatinostat是一种选择性的 I 类 HDAC 抑制剂，对 HDAC1、HDAC2 和 HDAC3 的 IC50 分别为 1.20 μM、1.12 μM 和 0.57 μM，也能抑制 LSD1 活性。

Domatinostat 化学结构
CAS号：910462-43-0

Domatinostat 3D分子结构
CAS号：910462-43-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Domatinostat 纯度/质量文件产品仅供科研

货号：A161236 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-A (Maize), IC50: 100 nM HD1-B (Maize), IC50: 3.4 μM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	HER2,EGFR	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											p53,NF-κB	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Domatinostat 生物活性

靶点	HDAC10 HDAC10, IC50:21 μM HDAC3 HDAC3, IC50:0.57 μM HDAC9 HDAC9, IC50:50 μM HDAC11 HDAC11, IC50:9.7 μM
描述	Domatinostat (4SC-202 free base) tosylate has been identified as a significant inhibitor of proliferation across both epithelial and mesenchymal urinary carcinoma (UC) cell lines, showcasing IC50 values ranging from 0.15 to 0.51 μM. Domatinostat also induces apoptosis in colorectal cancer (CRC) cells, a process which can be notably mitigated by caspase inhibitors such as z-VAD-CHO and z-DVED-CHO, suggesting its cytotoxic effects are, in part, mediated through caspase activation. Additionally, Domatinostat induces a significant G2-M phase arrest in CRC cells. Research suggests that AKT activation might play a crucial role in resistance to Domatinostat's cytotoxic effects. The cytotoxicity induced by Domatinostat is greatly enhanced under conditions of serum starvation, inhibition of AKT (via perifosine or MK-2206), or AKT1-shRNA knockdown in CRC cells. Conversely, the expression of constitutively active AKT1 (CA-AKT1) can reduce the sensitivity to Domatinostat in HT-29 cells. Remarkably, at low concentrations, Domatinostat can augment the anti-CRC activity of oxaliplatin in vitro. In the context of hepatocellular carcinoma (HCC), Domatinostat exhibits potent cytotoxic and anti-proliferative effects against both established HCC cell lines (such as HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. It activates apoptosis signal-regulating kinase 1 (ASK1), which then moves to mitochondria and physically associates with Cyp-D, indicating a pathway through which Domatinostat induces apoptosis in HCC cells.
体内研究	Moreover, oral administration of Domatinostat inhibits the growth of HT-29 xenografts in nude mice, an effect that is significantly enhanced when combined with oxaliplatin. This synergistic effect highlights Domatinostat's potential as a powerful component of combination therapies for cancer treatment, particularly in colorectal and hepatocellular carcinomas.
体外研究	Domatinostat (4SC-202 free base) tosylate has been identified as a significant inhibitor of proliferation across both epithelial and mesenchymal urinary carcinoma (UC) cell lines, showcasing IC50 values ranging from 0.15 to 0.51 μM. Domatinostat also induces apoptosis in colorectal cancer (CRC) cells, a process which can be notably mitigated by caspase inhibitors such as z-VAD-CHO and z-DVED-CHO, suggesting its cytotoxic effects are, in part, mediated through caspase activation. Additionally, Domatinostat induces a significant G2-M phase arrest in CRC cells. Research suggests that AKT activation might play a crucial role in resistance to Domatinostat's cytotoxic effects. The cytotoxicity induced by Domatinostat is greatly enhanced under conditions of serum starvation, inhibition of AKT (via perifosine or MK-2206), or AKT1-shRNA knockdown in CRC cells. Conversely, the expression of constitutively active AKT1 (CA-AKT1) can reduce the sensitivity to Domatinostat in HT-29 cells. Remarkably, at low concentrations, Domatinostat can augment the anti-CRC activity of oxaliplatin in vitro. In the context of hepatocellular carcinoma (HCC), Domatinostat exhibits potent cytotoxic and anti-proliferative effects against both established HCC cell lines (such as HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. It activates apoptosis signal-regulating kinase 1 (ASK1), which then moves to mitochondria and physically associates with Cyp-D, indicating a pathway through which Domatinostat induces apoptosis in HCC cells.

Domatinostat 细胞实验

Cell Line Primary skin fibroblasts PANC1 and ASPC1 cells HFOB 1.19 SJSA-1 UM-MCC34 cells MKL-2 cells MKL-1 cells WaGa cells Panc1 cells BxPC3 cells L3.6 cells IMR90 human normal lung fibroblasts SKOV3 ovarian serous cancer cells TOV21G ovarian clear cell cancer cells Human lung fibroblasts (IMR90) Glioma stem cells (TGS01) Glioma stem cells (GS-Y03) Glioma stem cells (GS-Y01) MDA-MB-231 cells MCF10A cells PANC1 and ASPC1 spheroid cultures 4T1 cells PANC28 ASPC1 PANC1 PANC1 and ASPC1 spheroids	Concentration	Treated Time	Description	References
Primary skin fibroblasts	2.5 µM	24 hours	No G2M arrest or apoptosis observed	J Invest Dermatol. 2021 Apr;141(4):903-912.e4.
PANC1 and ASPC1 cells	0.5 µM and 1 µM	16 hours	To evaluate the effect of Domatinostat on CD133 protein expression, results showed Domatinostat reduced CD133 expression.	J Exp Clin Cancer Res. 2022 Apr 11;41(1):138.
HFOB 1.19	1 µM	24 hours	Inhibits cell growth and proliferation, increases histone H3 acetylation levels	Cancers (Basel). 2021 Aug 20;13(16):4199.
SJSA-1	1 µM	24 hours	Inhibits cell growth and proliferation, increases histone H3 acetylation levels	Cancers (Basel). 2021 Aug 20;13(16):4199.
UM-MCC34 cells	2.5 µM	24 hours	Induced G2M cell cycle arrest and apoptosis, upregulated APM component gene expression	J Invest Dermatol. 2021 Apr;141(4):903-912.e4.
MKL-2 cells	2.5 µM	24 hours	Induced G2M cell cycle arrest and apoptosis, upregulated APM component gene expression	J Invest Dermatol. 2021 Apr;141(4):903-912.e4.
MKL-1 cells	2.5 µM	24 hours	Induced G2M cell cycle arrest and apoptosis, upregulated APM component gene expression	J Invest Dermatol. 2021 Apr;141(4):903-912.e4.
WaGa cells	2.5 µM	24 hours	Induced G2M cell cycle arrest and apoptosis, upregulated APM component gene expression	J Invest Dermatol. 2021 Apr;141(4):903-912.e4.
Panc1 cells	1 µM	24 or 72 hours	4SC-202 significantly inhibited the proliferation of Panc1 cells and induced p21 expression.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
BxPC3 cells	1 µM	24 or 72 hours	4SC-202 significantly inhibited the proliferation of BxPC3 cells and induced p21 expression.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
L3.6 cells	1 µM	24 or 72 hours	4SC-202 significantly inhibited the proliferation of L3.6 cells and induced p21 expression.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
IMR90 human normal lung fibroblasts	500 nM	3 days	Domatinostat did not affect cell viability	Int J Mol Sci. 2023 Jun 28;24(13):10817.
SKOV3 ovarian serous cancer cells	125-250 nM	3 days	Domatinostat reduced FOXM1 mRNA and protein expression levels in a concentration-dependent manner	Int J Mol Sci. 2023 Jun 28;24(13):10817.
TOV21G ovarian clear cell cancer cells	125-250 nM	3 days	Domatinostat reduced FOXM1 mRNA and protein expression levels in a concentration-dependent manner	Int J Mol Sci. 2023 Jun 28;24(13):10817.
Human lung fibroblasts (IMR90)	500 nM	3 days	To evaluate the effect of Domatinostat on normal cells, results showed no significant impact on the growth of IMR90 cells at 500 nM.	Int J Mol Sci. 2022 Jul 22;23(15):8084.
Glioma stem cells (TGS01)	500 nM	3 days	To evaluate the inhibitory effect of Domatinostat on the growth of glioma stem cells, results showed that Domatinostat significantly inhibited the growth of TGS01 cells at 500 nM.	Int J Mol Sci. 2022 Jul 22;23(15):8084.
Glioma stem cells (GS-Y03)	500 nM	3 days	To evaluate the inhibitory effect of Domatinostat on the growth of glioma stem cells, results showed that Domatinostat significantly inhibited the growth of GS-Y03 cells at 500 nM.	Int J Mol Sci. 2022 Jul 22;23(15):8084.
Glioma stem cells (GS-Y01)	500 nM	3 days	To evaluate the inhibitory effect of Domatinostat on the growth of glioma stem cells, results showed that Domatinostat significantly inhibited the growth of GS-Y01 cells at 500 nM.	Int J Mol Sci. 2022 Jul 22;23(15):8084.
MDA-MB-231 cells	100 nM to 10 µM	6 days	To evaluate the cytotoxic and cytostatic effects of 4SC-202 on MDA-MB-231 cells, showing significant reduction in colony formation at concentrations of 100 nM to 10 µM	Cancers (Basel). 2022 Mar 30;14(7):1753.
MCF10A cells	1 to 10 µM	7 days	To evaluate the toxicity of 4SC-202 on normal breast epithelial cells, showing no cytotoxicity to MCF10A cells at concentrations ranging from 1 to 10 µM	Cancers (Basel). 2022 Mar 30;14(7):1753.
PANC1 and ASPC1 spheroid cultures	0.5 µM	7 days	To evaluate the effect of Domatinostat on pancreatic cancer stem cell spheroid formation, results showed Domatinostat reduced spheroid numbers.	J Exp Clin Cancer Res. 2022 Apr 11;41(1):138.
4T1 cells	0.1 nM to 10 µM	72 hours	To evaluate the cytotoxic effects of 4SC-202 on 4T1 cells, showing significant reduction in cell viability at concentrations ranging from 0.1 µM to 10 µM	Cancers (Basel). 2022 Mar 30;14(7):1753.
PANC28	0.5 µM	96 hours	To evaluate the anti-tumor effect of Domatinostat in combination with chemotherapeutic agents, showing synergistic anti-proliferative and pro-apoptotic effects.	J Exp Clin Cancer Res. 2022 Mar 3;41(1):83.
ASPC1	0.5 µM	96 hours	To evaluate the anti-tumor effect of Domatinostat in combination with chemotherapeutic agents, showing synergistic anti-proliferative and pro-apoptotic effects.	J Exp Clin Cancer Res. 2022 Mar 3;41(1):83.
PANC1	0.5 µM	96 hours	To evaluate the anti-tumor effect of Domatinostat in combination with chemotherapeutic agents, showing synergistic anti-proliferative and pro-apoptotic effects.	J Exp Clin Cancer Res. 2022 Mar 3;41(1):83.
PANC1 and ASPC1 spheroids	0.5 µM and 1 µM		To evaluate the effect of Domatinostat on spheroid viability, results showed Domatinostat reduced spheroid viability.	J Exp Clin Cancer Res. 2022 Apr 11;41(1):138.

Domatinostat 动物实验

Species NMRI foxn1nu/nu mice Athymic mice Athymic mice BALB/c mice BALB/c mice Athymic nude mice	Animal Model Subcutaneous xenograft model of pancreatic cancer with L3.6 cells PANC28 and PANC1 xenograft models Pancreatic cancer xenograft model CT26 tumor model 4T1 breast cancer model Human osteosarcoma xenograft model	Administration	Dosage	Frequency	Description	References
NMRI foxn1nu/nu mice	Subcutaneous xenograft model of pancreatic cancer with L3.6 cells	Oral gavage	120 mg/kg	Twice daily for 4 days	4SC-202 significantly inhibited tumor growth.	Nucleic Acids Res. 2017 Jun 20;45(11):6334-6349.
Athymic mice	PANC28 and PANC1 xenograft models	Oral	20 mg/kg	5 days/week, for 3 weeks	To evaluate the anti-tumor effect of Domatinostat in combination with chemotherapeutic agents, showing significant reduction in tumor volume and synergistic anti-tumor effects.	J Exp Clin Cancer Res. 2022 Mar 3;41(1):83.
Athymic mice	Pancreatic cancer xenograft model	Oral	20 mg/kg	5 days/week for two weeks	To evaluate the effect of Domatinostat alone or in combination with chemotherapy on pancreatic cancer xenografts, results showed Domatinostat enhanced chemotherapy efficacy.	J Exp Clin Cancer Res. 2022 Apr 11;41(1):138.
BALB/c mice	CT26 tumor model	Oral	20 mg/kg twice daily or 60 mg/kg once daily	12-14 days (CT26) or up to 24 days (C38)	Domatinostat reduced tumor volume in immunocompetent mice, increased the number of CTLs in the tumor core, improved the CTL/Treg ratio, and enhanced antitumor immune responses.	J Immunother Cancer. 2019 Nov 8;7(1):294
BALB/c mice	4T1 breast cancer model	Intraperitoneal injection	50 mg/kg	Three times per week for 21 days	To evaluate the effects of 4SC-202 on tumor growth and metastasis, showing that 50 mg/kg dose significantly reduced tumor burden and lung metastasis	Cancers (Basel). 2022 Mar 30;14(7):1753.
Athymic nude mice	Human osteosarcoma xenograft model	Intraperitoneal injection	50 mg/kg/day	Once daily for 16 days	Reduces tumor growth, tumor mass significantly decreased by 70.56%	Cancers (Basel). 2021 Aug 20;13(16):4199.

Domatinostat 动物研究

Animal Administration	Mice: min = 80 mg/kg^[1], max = 120 mg/kg^[2]
Dose	Mice: min = 80 mg/kg^[1] (p.o.), max = 120 mg/kg^[2] (p.o.)
Administration	p.o.

Domatinostat 参考文献

[1]Pinkerneil M, et al. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target Oncol. 2016 Dec;11(6):783-798.

[2]Zhijun H, et al. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016 Aug;37(8):10257-67.

[3]Fu M, et al. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016 Mar 4;471(2):267-73

Domatinostat 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.17mL

2.23mL

1.12mL

22.35mL

4.47mL

2.23mL

Domatinostat 技术信息

CAS号	910462-43-0
分子式	C₂₃H₂₁N₅O₃S
分子量	447.51
SMILES Code	O=C(NC1=CC=CC=C1N)/C=C/C2=CN(S(=O)(C3=CC=C(C4=CN(C)N=C4)C=C3)=O)C=C2
MDL No.	MFCD28155264

别名	4SC-202 free base; 4SC-202
运输	蓝冰
InChI Key	PRXXYMVLYKJITB-IZZDOVSWSA-N
Pubchem ID	15985904

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

溶解方案

细胞实验：

DMSO: 55 mg/mL(122.9 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

Domatinostat {[allProObj[0].p_purity_real_show]}

Domatinostat 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Domatinostat 质控信息

Domatinostat 生物活性

Domatinostat 细胞实验

Domatinostat 动物实验

Domatinostat 动物研究

Domatinostat 参考文献

Domatinostat 实验方案

Domatinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

HDAC10	HDAC10, IC50:21 μM
HDAC3	HDAC3, IC50:0.57 μM
HDAC9	HDAC9, IC50:50 μM
HDAC11	HDAC11, IC50:9.7 μM
HDAC5	HDAC5, IC50:11.3 μM
HDAC2	HDAC2, IC50:1.12 μM
HDAC1	HDAC1, IC50:1.20 μM

Domatinostat {[allProObj[0].p_purity_real_show]}

Domatinostat 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Domatinostat 质控信息

Domatinostat 生物活性

Domatinostat 细胞实验

Domatinostat 动物实验

Domatinostat 动物研究

Domatinostat 参考文献

Domatinostat 实验方案

Domatinostat 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Domatinostat 纯度/质量文件产品仅供科研